Putting aside the usual anti-pharma narrative for a moment, Merck, which is seeking emergency use authorizat
Drugs & Pharmaceuticals
Atea Pharmaceuticals, which is (was?) co-developing another COVID antiviral drug with Roche called AT-527, issued a
Without a significant pull incentive, our pipeline of new antibacterials is doomed. This must be our top priority.
This year’s influenza (“flu”) season, which has already begun in some parts of the country, revs up in November, and last until spring, will be made more ominous than ever by the current high numbers of COVID-19 cases in many parts of the nation.&
As Professor Katherine Seley-Radtke (1) and I wrote last July in an op
Why are so many Americans unwilling to get a COVID-19 vaccine?
Remember back in the early days of COVID when we knew little about the disease and had nothing to treat it with? Remdesivir (brand name Veklury®) seemed promising for a while, but as I wrote last year:
The race to discover anti-COVID drugs, just like the race to discover any drugs, has been long (1) and frustrating.
I'm sure seeing a lot of vaccine disquietude going around in the past few months.
April Fool's Day is seven months away. Otherwise, I'm betting that most of you would write this off as just another joke article. Don't.